Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
Date:8/12/2008

>

safety and pharmacokinetics of MAP0004 in adults in Headache.

-- Delivered over 15 oral and poster presentations related to UDB and

MAP0004 at annual scientific conferences including: American

Academy of Allergy Asthma & Immunology (AAAAI), American Academy

of Neurology (AAN), Respiratory Drug Delivery (RDD), American

Thoracic Society (ATS) and American Headache Society (AHS).

-- Corporate progress

-- Added seasoned industry veterans to the management team and board

of directors, including: Donald J. Kellerman, Pharm.D. to the

position of Senior Vice President, Clinical Development and

Medical Affairs; Marco F. Rosa to the position of Vice President

of Human Resources; and H. Ward Wolff to the board of directors

and audit committee.

-- Secured a $20 million working capital loan to repay the existing

working capital loan and for general corporate purposes.

-- Acquired proprietary drug particle formulation technology from

Telesso Technologies Limited, formerly Eiffel Technologies

Limited.

"We continue to make progress toward our goal of providing better medicines to patients, with clearly differentiated product benefits for undermet medical needs," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "With two product candidates now in Phase 3 studies, we remain focused on building the team, infrastructure and resources we need to advance MAP Pharmaceuticals through Phase 3 trials, toward commercializing products that address major market opportunities."

Second Quarter and Six Month Financial Results

Research and development expenses for the second quarter and six months ended June 30, 2008 were $13.0 million and $24.8 million, respectively, compared to $6.3 million and $10.8 million, res
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
3. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
4. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
5. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
6. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris ... college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio ... expand its reach and impact through innovative technologies and strategies. , “I am very ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... until it encounters a cancer cell, then suddenly activates and ... marks the latest step in scientists, efforts to tap the ... of the technology at the University of Rochester Medical Center ... machines produced in abundance by tumors to chew through and ...
... a major public health problem through its association with ... life expectancy rises around the world, along with the ... incidence of hip fractures is estimated to reach 6.3 ... of fracture in men and women. A new review ...
... on the words ,light, and ,mild, smokers in Western ... may be less harmful than others. In fact, ... of risk to smokers, including ,mild, and ,low-tar, brands. ... Addiction polled over 8000 smokers from Australia, Canada, ...
... Amanda Gardner HealthDay Reporter , MONDAY, April 11 ... primary care doctors often choose a different option than they ... In fact, physicians who were surveyed in the research more ... to have long-term repercussions, such as paralysis, than to die. ...
... University researcher has co-authored an international study that revealed a ... treat a rare lung disease in women. The life-threatening ... The clinical trial of the drug -- called sirolimus ... a therapy for the lung disease, lymphangioleiomyomatosis, or LAM. ...
... -- Long-term use of antibiotics to treat acne doesn,t ... medications, a new study finds. The finding came ... of antibiotics has been credited with encouraging antibiotic resistance ... Pennsylvania School of Medicine assessed the prevalence of ...
Cached Medicine News:Health News:A 'Pacman strategy' to boost the immune system to fight cancer 2Health News:A 'Pacman strategy' to boost the immune system to fight cancer 3Health News:Changing trends in hip fracture incidence around the world 2Health News:Smokers believe 'silver', 'gold' and 'slim' cigarettes are less harmful 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 3Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Acne Antibiotics Not Linked to Drug Resistance 2
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... MYL ) shareholder vote regarding its planned unsolicited offer ... offer to Perrigo shareholders have always been, and will ... of the value available to Perrigo shareholders, and do ... allowed its shareholders to consider," said Joseph C. ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Merrimack Pharmaceuticals, Inc. announced today that the first ... study combining MM-121, a fully human monoclonal antibody that ... for patients with advanced solid tumors. ... evaluates the safety and pharmacokinetics of MM-121 when administered ...
... LLC has hired nutritional brand marketing expert Tom Hall ... will apply his 30 years of executive marketing experience ... to launch new company products in the international marketplace. ... "Tom,s extensive experience and success in product ...
Cached Medicine Technology:Tom Hall Named National Sales and Marketing Director for VR Laboratories 2Tom Hall Named National Sales and Marketing Director for VR Laboratories 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: